Augnito vs Speke (2026)
Two ambient products from companies that were doing this work with people and dictation long before models could. Augnito comes from a transcription business with more than two decades in a national health service estate, and it pairs clinical speech recognition with ambient documentation in one platform, which suits an organization migrating clinicians from dictation rather than starting fresh. Speke comes from the largest human medical scribe company in the United States, with over a thousand clients behind it, so its automation spectrum runs from a fully drafted note to a human scribe without changing supplier. Neither publishes an accuracy figure. The real question for both is the same one their pure play competitors never have to answer: as the automated tier absorbs more of the volume, what happens to the humans in the service and to the price you were quoted.
- Two decades of clinical speech work behind it, with deep experience in a national health service estate, which is a different operating environment from United States ambulatory practice.
- Speech recognition and ambient documentation in one platform, so an organization moving clinicians from dictation to ambient capture does not change vendor midway.
- For non United States deployments, the regulatory and procurement experience is already in the company rather than being acquired on your project.
- It comes from the largest human medical scribe company in the United States, serving over a thousand clients, which is an installed base no pure play can match.
- The human tier is the company's core business rather than an option, so a practice can move along the automation spectrum without changing supplier.
- For a health system already using scribe services, this is continuity rather than a new vendor relationship and a new security review.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Augnito and Speke are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Augnito | Speke |
|---|---|---|
| Primary category | Ambient Scribes | Ambient Scribes |
| Founded | 2020 | Not recorded |
| Headquarters | United Kingdom and India | Fort Lauderdale, Florida, United States |
| Website | augnito.ai | spekeai.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Augnito is the clinical speech and ambient documentation platform from Scribetech, a medical transcription company with more than two decades of NHS work behind it, operating as Scribetech (UK) Ltd and Augnito India Private Limited. Its ambient product Omni captures in clinic, video and telemedicine consultations and produces structured notes, clinical and referral letters, documentation feedback, coding in ICD-10 and SNOMED, and live translation into the electronic patient record.
Source: AI Health Index, August 2026
Speke is the ambient AI scribe from the HealthChannels family, whose brands include ScribeAmerica, the largest human medical scribe company in the United States, serving over 1,000 clients across more than 3,000 sites and around 30 million encounters a year. Ambient capture generates the note, and at the enterprise tier trained specialists perform quality assurance and editing before it reaches the clinician for approval.
Source: AI Health Index, August 2026
Questions buyers ask
How do Augnito and Speke handle patient data?
For Augnito, the parent company has supplied clinical transcription to the health service and private providers since 2001, with delivery teams in England and India.
On Speke AI Pro, trained clinical support specialists perform quality assurance and editing, so recorded clinical conversation and draft documentation are read by people as well as processed by a model, which is a larger and more variable exposure surface. Speke AI Express, the self serve tier, carries no such review. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Augnito and Speke cover?
In Augnito's case, the community nursing use case, where the clinician is rarely near a desktop, is addressed explicitly.
For Speke, the published figure is inconsistent, appearing as 25 or more in one section and 30 or more in the pricing tiers on the same page. Site specific templates, macros and dot phrases carry over per provider, which is the practical form specialty coverage takes for a clinician switching from a human scribe. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How much do Augnito and Speke leave to the clinician?
With Augnito, the product does not stop at a note. It generates and sends clinical letters, captures clinical coding, and performs live translation during the consultation.
In Speke's case, the vendor's own material states this both ways. The homepage describes a professional reviewing the note for accuracy before submission as part of how the product works, while the feature lists and the Pro page place that review in the enterprise tier. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Both vendors carry a legacy services business alongside the AI product, so the commercial comparison is not like for like against a per clinician software subscription and depends on the mix of automated and human reviewed work. Neither publishes an accuracy figure, model card or evaluation methodology. Neither publishes a rate card.
For any deployment outside the United States, establish which regime governs the product in that market rather than assuming the United States position transfers, and for any deployment inside it, ask what the service level looks like when the automated tier cannot produce an acceptable note.